Alkermes plc (ALKS) fair value analysis

Nasdaq · Updated 2026-09-07

Alkermes plc is a biopharmaceutical company that develops and commercializes medicines for the treatment of central nervous system disorders, including schizophrenia, bipolar disorder, and opioid addiction. The company operates globally with operations in the United States, Ireland, and other international markets.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, ALKS is trading at more than a 25% premium to estimated fair value.

ALKS currently ranks #113 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $49.53
Sector: Healthcare
12-month range: $28.26–$51.72

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for ALKS

Our model validated 16 trailing price-to-earnings windows for ALKS, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $28.26–$51.72.
The 14-day relative strength index sits at a neutral 35.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ALKS
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ALKS news

TickrTrends' derived news-sentiment signal for ALKS is currently leaning positive, computed from recent coverage.

Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares (gurufocus.com, 2026-09-04)
TickrTrends take: An executive sale by Alkermes' EVP and Chief Legal Officer represents insider activity that warrants consideration alongside the company's current valuation standing. TickrTrends' Overvalued designation for ALKS suggests the stock may face headwinds, making insider selling patterns potentially significant to monitor as additional context for valuation decisions. For healthcare sector investors, such insider transactions can provide signals about management's own confidence levels relative to current market pricing, particularly when a company is trading above fundamental valuation benchmarks.
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 (finance.yahoo.com, 2026-08-29)
TickrTrends take: The sale by Alkermes' Chief Commercial Officer represents an insider transaction that valuation-focused investors track as a potential signal of management's confidence in current pricing. With TickrTrends assessing ALKS as overvalued, insider selling at this juncture may reinforce concerns about the stock's current valuation relative to its fundamentals in the Healthcare sector. Investors monitoring the company should observe whether this transaction reflects broader management views on the stock's valuation sustainability or represents routine portfolio rebalancing.
Alkermes PLC (ALKS) Stock Down 3.1% but Still Overvalued -- GF Score: 64/100 (gurufocus.com, 2026-08-29)
TickrTrends take: Alkermes has experienced recent downward price movement, yet TickrTrends maintains its assessment that the stock remains overvalued relative to fundamental metrics. For investors focused on valuation, the company's GF Score of 64 out of 100 suggests moderately positive underlying fundamentals that may not justify current pricing in the Healthcare sector. Monitoring whether further price declines bring ALKS closer to a fair valuation level would be relevant for value-oriented market participants.

What people are saying

Follow the ALKS conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — # ALKS Weekly Indicator Summary TickrTrends' derived indicators for ALKS show a weakening momentum signal this week, with the momentum indicator declining from a C rating to none. The stock remains classified as overvalued according to current valuation metrics. This combination of deteriorating momentum and elevated valuation suggests reduced upside catalysts in the near term for the healthcare sector company.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ALKS stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ALKS is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is ALKS's TickrTrends verdict?

ALKS's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does ALKS compare to other Healthcare stocks?

ALKS ranks #113 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ALKS overbought or oversold?

ALKS's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ALKS vs ACAD · ALKS vs AMGN · ALKS vs CDNA · ALKS vs DGX · ALKS vs GILD